- EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS
-
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
- -
-
Paragraph 0405; 0423
(2021/01/23)
-
- 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION
-
The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease
- -
-
Paragraph 000460-000461
(2021/11/26)
-
- BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
-
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
- -
-
Paragraph 0690-0692
(2021/05/14)
-
- COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
-
The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and pharmaceutically acceptable slats thereof, pharmaceutical compositions comprising such compounds and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof.
- -
-
Page/Page column 78
(2020/08/22)
-
- HETEROCYCLIC COMPOUND
-
The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.
- -
-
-
- METHOD FOR PRODUCING 2-AMINO-4-(TRIFLUOROMETHYL)PYRIDINE
-
The present invention relates to a process for producing a 2-amino-4-trifluoromethylpyridine. Specifically, the present invention provides a process for producing a compound represented by the formula (I) or a salt thereof: (in the formula, X1 is the same as X1 in the formula (II) below), which includes allowing a compound represented by the formula (II): (in the formula, each of X1 and X2 is independently a chlorine atom or a bromine atom) to react with ammonia in the presence of a hydrophilic ether; and also a process for producing 2-amino-4-trifluoromethyl pyridine or a salt thereof, which comprises subjecting the compound of the formula (I) as produced by the foregoing process to dehalogenation,
- -
-
Page/Page column 5
(2012/12/13)
-
- TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS
-
The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatorydiseases, cardiovascular disceases and/or neurodegenerative diseases and a process for their preparation.
- -
-
Page/Page column 58-59
(2009/04/25)
-
- NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES
-
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
- -
-
Page/Page column 31
(2009/06/27)
-